CMP-002: A Development Candidate Antisense Oligonucleotide Targeting a SYNGAP1 Regulatory RNA For The Potential Treatment of SYNGAP1-Related Disorder

Camp4 Therapeutics Corporation published this content on July 08, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 08, 2026 at 21:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]